NRx Pharmaceuticals Appoints Michael Abrams as CFO
Portfolio - People | Nov 18, 2024 | EIN
NRx Pharmaceuticals, a clinical-stage biopharmaceutical company, has appointed Michael Abrams as its new CFO. Abrams replaces interim CFO Richard Narido, who will stay with the company in other capacities. Abrams brings decades of experience in finance, most notably in roles within the biotechnology sector and investment banking. The announcement underscores NRx's strategic efforts to transition into a revenue-generating company. NRx Pharmaceuticals is known for developing therapeutics for central nervous system disorders. The company is making strides in NDA submissions for its breakthrough therapies aimed at treating bipolar depression, chronic pain, and other conditions. Additionally, NRx's development of NRX-100, based on results from trials in conjunction with the NIH, positions the company for accelerated development pathways with Fast Track designation from the FDA. HOPE Therapeutics, a related entity, aims to create a precision psychiatry clinic network and is involved in forward-looking ventures that may affect NRx's growth strategy.
Sectors
- Biopharmaceutical
- Healthcare Services
- Financial Services
Geography
- United States – NRx Pharmaceuticals and HOPE Therapeutics are based in the United States, with regulatory interactions, including the FDA, critical to their strategic operations.
Industry
- Biopharmaceutical – NRx Pharmaceuticals operates within the biopharmaceutical industry, focusing on the development of therapeutics for central nervous system disorders.
- Healthcare Services – HOPE Therapeutics, a related entity, is developing a network of precision psychiatry clinics, emphasizing healthcare delivery services.
- Financial Services – The appointment of a new CFO highlights aspects of financial strategy and operations within NRx Pharmaceuticals, involving financial planning and investor relations.
Financials
- N/A – No specific financial details or transaction values were mentioned in the article.
Participants
| Name | Role | Type | Description |
|---|---|---|---|
| NRx Pharmaceuticals, Inc. | Company | Target Company | A clinical-stage biopharmaceutical company focused on developing treatments for central nervous system disorders. |
| Michael Abrams | Chief Financial Officer | Person | Newly appointed Chief Financial Officer of NRx Pharmaceuticals, with a background in biotechnology and investment banking. |
| Richard Narido | Interim Chief Financial Officer | Person | The outgoing interim CFO of NRx Pharmaceuticals, who will continue to support the company's financial functions. |
| HOPE Therapeutics, Inc. | Other Company | Company | A development-stage healthcare company affiliated with NRx, focused on building a network of precision psychiatry clinics. |
| Dr. Jonathan Javitt | Chairman, CEO and Chief Scientist | Person | Leader of NRx Pharmaceuticals, instrumental in its strategic and scientific direction. |